RobertTurnerSchooleyMD

Infectious Disease • La Jolla, CA

HIV/AIDS Medicine, International Health, Travel & Tropical

Professor, Medicine, UCSD School of Medicine

Join to view full profile

Dr. Schooley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schooley's full profile

Already have an account?

Office
University of California San Diego
Stein Clinical Research Building
La Jolla, CA 92093
Phone+1 858-246-2693

Education & Training

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1979 - 1981
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1976 - 1979
Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
Johns Hopkins UniversityInternship, Internal Medicine, 1974 - 1975
Johns Hopkins University School of MedicineClass of 1974
Washington and Lee UniversityBS, 1970

Certifications & Licensure

CA State Medical License 2005 - 2026
CO State Medical License 1990 - 2025
MD State Medical License 1974 - 1983
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Who's Who in America 1995-2018
Gold Doc Arnold P. Gold Foundation, 2009
Chief Residents’ Clinical Teaching University of California, San Diego, 2007
Science of Medicine Bonfils-Stanton Foundation, 1999
Honorary Professor Peking Union Medical College, Beijing, China, 1999
America’s Top Doctors 1997, 2013
Who’s Who in the West 1993, 2013
Who’s Who in Healthcare and Technology 1993, 2013
Best Doctors in America 1992, 2013
Elected Member Association of American Physicians, 1992, 1995, 2013
John Enders Memorial Lectureship Infectious Disease Society of America, 1991
Elected Member The American Society for Clinical Investigation, 1990
New Investigator NIAID, NIH, 1980, 1983
Omicron Delta Kappa 1970
Join now to see all

Clinical Trials

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
Completed
Phase 1
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
Completed
Phase 1
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients Start of enrollment: 2004 Jun 01
Completed
Phase 2
Respiratory Virus Outpatient Study (FLU 002 Plus) Start of enrollment: 2009 Aug 01
Completed
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa Start of enrollment: 2022 Oct 03
Recruiting
Phase 1, Phase 2
Roles: Contact
Respiratory Virus Hospitalization Study (FLU 003 Plus) Start of enrollment: 2009 Aug 01
Recruiting
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

3914 citations
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework*
Arthur J. Atkinson, Wayne A. Colburn, Victor G. DeGruttola, David L. DeMets, Gregory J. Downing
Clinical Pharmacology and Therapeutics. 2001-01-01
180 citations
Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission.
Smruthi Karthikeyan, Joshua I Levy, Peter De Hoff, Greg Humphrey, Amanda Birmingham
Nature. 2022-09-01
175 citations
Phage therapy: From biological mechanisms to future directions.
Steffanie A Strathdee, Graham F Hatfull, Vivek K Mutalik, Robert T Schooley
Cell. 2023-01-05

Journal Articles

Successful Treatment of Antibiotic Resistant Poly-Microbial Bone Infection with Bacteriophages and Antibiotics Combination
Robert Schooley, MD, Clinical Infectious Diseases
Oa the Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and Mozambique
Robert Schooley, MD, The American Journal of Tropical Medicine and Hygiene
The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies
Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases
Herd Immunity Likely Protected the Men Who Have Sex with Men in Recent Hepatitis A Outbreak in San Diego CA
Robert Schooley, MD, Clinical Infectious Diseases
Effects of cycloheximide on the response of intestinal mucosa to cholera enterotoxin.
Kimberg DV, Field M, Gershon E, Schooley RT and Henderson A, J Clin Invest. 1973; 52:1376-83
Edema associated with ibuprofen therapy.
Schooley RT, Wagley PF and Lietrnan PS, JAMA. 1977; 237:1716-7
Adult-onset acid maltase deficiency. Case report of an adult with severe respiratory difficulty.
Lightman NI and Schooley RT, Chest. 1977; 72:250-2
Characterization of thymus-derived lymphocyte subsets in acute Epstein-Barr virus-induced infectious mononucleosis.
Haynes BF, Schooley RT, Grouse JE, Payling-Wright CR, Dolin R and Fauci AS, J Immunol. 1979; 122:699-702
Emergence of suppressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis.
Haynes BF, Schooley RT, Payling-Wright CR, Grouse J, Dolin R and Fauci AS, J Immunol. 1979; 123:2095-101
Mechanism of Epstein-Barr virus-induced human B-lymphocyte activation.
Schooley RT, Haynes BF, Payling-Wright CR, Grouse J, Dolin R and Fauci AS, Cellular Immunol. 1980; 56:518-25
Facial erysipelas in the immunocompromised host. Report of two cases.
Cupps TR, Cotton DJ, Schooley RT and Fauci AS, Arch Dermatol. 1981; 117:47-9
Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia.
Wasson DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS and Gleich GJ, J Clin lnvest. 1981; 67:651-61
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations.
Flaum MA, Schooley RT, Fauci AS and Gralnick HR, Blood. 1981; 58:1012-20
A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.
Schooley RT, Flaum MA, Gralnick HR and Fauci AS, Blood. 1981; 58:1021-6
Development of suppressor T-lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: Assessment by two quantitative sys...
Schooley RT, Haynes BF, Grouse J, Payling-Wright CR, Fauci AS and Dolin R, Blood. 1981; 57:510-7
The effect of infection of T-lymphocyte subpopulations: a preliminary report.
Rubin RH, Carney WP, Schooley RT, Colvin RB, Burton RC, Hoffman RA, Hansen WP, Cosimi AB, Russell PS and Hirsch MS, Int J lmmunopharmacol. 1981; 3:307-12
Detection by immune electron microscopy of Snow Mountain agent of acute viral gastroenteritis.
Dolin R, Reichman RC, Roessner KD, Tralka TS, Schooley RT, Gary W and Morens D, J Inf Dis. 1982; 146:184-9
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts.
Thorley-Lawson DA, Schooley RT, Bhan AK and Nadler LM, Cell. 1982; 30:415-25
Mass mortality of harbor seals: pneumonia associated with influenza A virus.
Geraci JR, St. Austin DJ, Barker, IK, Webster RG, Hinshaw VS, Bean WJ, Ruhnke HL, Prescott JH, Early G, Baker AS, Madoff S and Schooley RT, Science. 1982; 215:1129-31
Monoclonal antibody against EBV-associated transformation antigen detected in vitro and in vivo.
Thorley-Lawson DA, Geilinger K and Schooley RT, Protides Biol Fluid Colloq. 1982; 29:739-42
Serological responses and systemic reactions in adults with monovalent A/USSR/77 and trivalent A/USSR/77-A/Texas/77-B/Hong Kong/72 influenza vaccine.
Quinnan GV, Schooley RT, Dolin R, Ennis FA, Gross P and Gwaltney JM, Rev Infect Dis. 1983; 5:748-57
Two-dimensional echocardiographic assessment of the idiopathic hyper-eosinophilic syndrome. Anatomic basis of rnitral regurgitation and peripheral embolization.
Gottdiener JS, Maron BJ, Schooley RT, Harley JB, Roberts WC and Fauci AS, Circulation. 1983; 67:572-8
Analysis of cellular immune response to EBV by using cloned T cell lines.
Slovin SF, Schooley RT and Thorley-Lawson DA, J Immunol. 1983; 130:2127-32
Association of herpes virus infections with T-lymphocyte subset alterations, glomerulopathy, and opportunistic infections following renal transplantation.
Schooley RT, Hirsch MS, Colvin R.B, Cosimi AB, Tolkoff-Rubin NE, McCluskey RT, Burton RC, Russell PS, Herrin JT, Delmonico FL, Giorgi JV, Henle W and Rubin RH, N Engl J Med. 1983; 308:307-13
Phenotypic analysis of New World primate mononuclear cell surface antigens.
Schooley RT, Byington R and Falk Jr. LA, J Med Primatology. 1983; 12:30-40
Join now to see all

Books/Book Chapters

Current Clinical Topics in Infectious Diseases.
Chapter: Chronic Fatique Syndrome: A Manifestation of Epstein-Barr Virus Infection?
Page 126 - 146Schooley RTEditors: JS Remington and MN Swartz.McGraw-Hill Book Co
Host Responses to Infections in Infectious Diseases.
Page 30 - 44Wilson CC and Schooley RTMosby Elsevier, LondonEdition 3,
Cecil’s Textbook of Internal Medicine.
Chapter: Epstein Barr Virus Infection
Schooley RT
Mechanisms of Microbial Diseases.
Chapter: Human Retroviruses: AIDS and Other Diseases
Page 376 - 388Schooley RTEditors: Engleberg NC, DiRita V and Dermody TS.Lippincott Williams and WilkinsEdition 4,
AIDS and Other Manifestations of HIV Infection.
Chapter: Antiretroviral Chemotherapy
Page 827 - 840Schooley RTEditors: G.P. Wormser.Raven Press, New YorkEdition 4,
Principles and Practice of Infectious Diseases.
Chapter: Epstein-Barr Virus (Infectious Mononucleosis)
Schooley RT and Dolin RJohn Wiley and Sons, New YorkEdition 4,
Principles and Practice of Infectious Diseases.
Chapter: Chronic Fatigue Syndrome
Schooley RTJohn Wiley and Sons, New YorkEdition 4,
Textbook of AIDS Medicine.
Chapter: Immune Based Therapies for HIV-1 Infection
Page 713 - 720Schooley RTEditors: S. Broder, D.P. Bolognesi and T.C. Merigan, Jr.Williams and Wilkins, Baltimore
HIV Molecular Organization, Pathogenicity and Treatment.
Chapter: HIV-1 Specific Immune Responses
Page 75 - 98Connick E and Schooley RTEditors: W.J.W. Morrow and N. Haigwood.Elsevier Science Publishers, The Netherlands
AIDS and Other Manifestations of HIV Infection.
Chapter: Antiretroviral Chemotherapy
Page 609 - 623Schooley RTEditors: G.P. Wormser.Raven Press, New York
AIDS: Etiology, Diagnosis, Treatment, and Prevention.
Chapter: Herpesvirus Infection in Individuals with HIV Infection
Page 193 - 207Schooley RTEditors: V.T. DeVita, S. Hellman and S.A. Rosenberg, J.B.Lippincott Company, PhiladelphiaEdition 3,
Neurological and Neurosurgical Intensive Care.
Chapter: Encephalitis
Page 411 - 435Schooley RTEditors: A.H. Ropper.Raven Press, New YorkEdition 3,
Respiratory Disease in the Immunosuppressed Host.
Chapter: Pneumonia Due to Herpesviruses
Page 386 - 397Schooley RTEditors: J Shelhamer, et al.Lippincott Company, Philadelphia
Merck Manual of Diagnosis and Theapy.
Chapter: Infectious Mononucleosis
Schooley RTMerck Sharp & Dohme Research Laboratories, Rahway, NJEdition 15,
Principles and Practice of Infectious Diseases.
Chapter: Epstein-Barr Virus (Infectious Mononucleosis)
Page 1172 - 1185Schooley RT and Dolin RJohn Wiley and Sons, New YorkEdition 3,
Clinical Approach to Infection in the Compromised Host.
Chapter: Morbidity in Compromised Patients Due to Viruses Other Than Herpes Group and Hepatitis Viruses
Schooley RTEditors: RH Rubin and LS Young.Plenum Book Company, New York and LondonEdition 2,
Principles and Practice of Infectious Diseases.
Chapter: Epstein-Barr Virus (Infectious Mononucleosis)
Page 1324 - 1341Schooley RT and Dolin RJohn Wiley and Sons, New York
HIV and Other Highly Pathogenic Viruses.
Chapter: Interferon Alpha in the Therapy of Patients with HW Infections
Page 113 - 124Schooley RTAcademic Press Inc, Roberts A. Smith
Perspectives for lymphokine therapy: from genetic engineering to immunologic engineering.
Page 131 - 42Schooley RTEditors: C. Th. Smit Sibinga, P.D. Das, C. P. Engelfriet.Nijhoff Publishing
Infections in Transplant Patients.
Chapter: Prophylactic and Therapeutic perspective in viral infections
Page 205 - 224Schooley RTGeorg Thieme Verlag Stuttgart
Neurological and Neurosurgical Intensive Care.
Chapter: Encephalitis
Page 289 - 307Schooley RTEditors: A. H. Ropper and S. F. Kennedy.Aspen Publication, Rockville, MarylandEdition 2,
Primary Care Medicine.
Chapter: AIDS
Page 637 - 641Schooley RTEditors: AM Gorell, LA May, AG Mulley.Lippincott, PhiladelphiaEdition 2,
Harrison's Textbook of Internal Medicine.
Chapter: Epstein Barr virus infections, including mononucleosis
Page 699 - 703Schooley RTMcGraw-Hill, New YorkEdition 11,
The Biology of the Interferon System.
Chapter: Interferon trials in immunocompromised patients
Hirsch MS and Schooley RTEditors: Kirchner H and Schellekens H.Elsevier, Amsterdam
Principles and Practice of Infectious Diseases.
Chapter: Epstein-Barr Virus (Infectious Mononucleosis)
Page 971 - 982Schooley RT and Dolin RJohn Wiley and Sons, New YorkEdition 2,
Join now to see all

Abstracts/Posters

Long-term propagation of New World primate T-lymphocytes in vitro.
Falk Jr. LA, Silva D, Byington R and Schooley RT, Fifteenth International Leukocyte Culture Conference. Intercell Communicat in Leucocyte Function

Other

Just (Don't) Do It.
Schooley RT, J Clin Invest. 1993; 92:535
Hepatitis C virus therapeutics: at the end of the beginning.
Schooley RT, Top Antivir Med. 2012; 20:17-9
Viral Load Testing in Resource Limited Settings.
Schooley RT, Clin Infect Dis. 2007; 44: 139-40
Starting highly active antiretroviral therapy for HIV infection: is it WIHS to wait?
Schooley RT, Ann Intern Med. 2004;140:305-6
Longer-term immunologic effects and side effects of successful antiretroviral therapy.
Schooley, RT, Clin Infect Dis. 1999; 29:12-8
Antiretroviral chemotherapy.
Saag MS and Schooley RT, Curr Clin Top Infect Dis. 1998; 18:154- 79
Check, but not checkmate.
Schooley RT, Antiviral Therapy. 1997; 2:68-9
Therapeutic decision making in 1997.
Cotton D, Bartlett J, Schooley R, Gulick R
Enhancing HIV-1 Specific Immunity as a Therapeutic Strategy in AIDS.
Schooley RT, Advances in Exper Med and Biol. 1996; 394:405-10
Immunomodulatory effects of antiretroviral chemotherapy.
Schooley RT, J Biol Regul Homeost Agents. 1995; 9:110-3
HIV-1 specific cytotoxic T-cell responses.
Schooley RT, AIDS. 1995; 9:S113-6
Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.
Schooley RT, AIDS. 1995; 9:S15-9
Epstein-Barr Virus: Current Concepts.
Schooley RT and Hirsch MS, Infect Disease Practice.1980; 3:1-7
Challenges in the clinical development of antiretroviral drugs.
Schooley RT, Antiviral Research. 1992; 17:305-10
Cytomegalovirus in the setting of infection with human immunodeficiency virus.
Schooley RT, Rev Infect Dis. 1990; 12:S811-9
Epstein-Barr virus.
Schooley RT, Current Opinion in Infectious Diseases. 1989; 2:267-71
Waltzing HIV-tilda (editorial).
Schooley RT, Arch Intern Med. 1988; 148(4):778
AIDS: Clinical Aspects and Biologic Therapies.
Schooley RT, Immunology and Allergy Clinics. 1988; 93-109
Chemotherapie und immunoprophylaxe der HIV-infektion.
Vogt M, Schooley RT and Hirsch MS, Schweizerische Rndschau fur Medizin Praxis. 1986; 75:1471-5
An overview of antiviral therapy of HTLV-III/LAV infection.
Vogt MW and Schooley RT, Noyes Publications
Are apheresis personnel at risk for AIDS Plasma Therapy & Transfusion Technology.
Vogt MW, Addison R, Schooley RT and Hirsch MS
Lymphocyte markers and infectious diseases.
Blumberg RS and Schooley RT, Seminars in Hematology. 1985; 22:81-114
How to manage infectious mononucleosis.
Schooley RT, Drug Therapy. December, 1983; 13:68-77
Susceptibility to Acquired Immune Deficiency Syndrome (AIDS): Clinical Practice Update.
Schooley RT, Volume 2, Number 4
Join now to see all

Press Mentions

Outbreak of Eyedrop-Linked Bacteria Kills Three, CDC ReportsMarch 22nd, 2023
After Dozens of Children at Local Hospital Test Positive for Bacteria, Tap Water Found to Be the SourceDecember 9th, 2022
Researchers Use Genetic Sequencing and Wastewater Analysis to Detect SARS-CoV-2 Variants and Monkeypox Within CommunitiesSeptember 12th, 2022
Join now to see all

Grant Support

Orally Active Nucleoside Phosphonates For Hepatitis C VirusNational Institute Of Allergy And Infectious Diseases2009–2012
Multiplex Nucleic Acid Detection Devices For The Diagnosis Of Respiratory VirusesNational Institute Of Allergy And Infectious Diseases2007–2011
International ProgramNational Institute Of Allergy And Infectious Diseases2006–2011
Research In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2005–2011
Biochip Diagnostic Tool For Bt Induced DiseasesNational Institute Of Allergy And Infectious Diseases2005–2007
The Role Of Sex And HCV Co-Infection In HIV TherapyNational Institute Of Allergy And Infectious Diseases2004
ACTG A5116:2 Regimen Trial For HIV SubjectsNational Center For Research Resources2004
U Of Colorado Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2003–2004
Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2003
Colorado Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2000–2003
University Of Colorado HIV Research Training ProgramNational Institute Of Allergy And Infectious Diseases1992–2003
Subcutaneous IL-2 In Combination With HaartNational Center For Research Resources2000–2002
Dynamics Of HCV Infection During Antiretroviral TherapyNational Center For Research Resources2000–2002
Chemotherapy/Immunotherapy For HIV InfectionNational Center For Research Resources2000–2002
Soft Gelatin Capsule Of Saquinavir In Comb WI Ritonavir Or NelfinavirNational Center For Research Resources1999–2002
Phase III Trial:Efavirenz/ Nelfinavir In Combination WI Lamivudine/ZidovudineNational Center For Research Resources1999–2002
Phase II Stdy Indinavir+Nevirapine+Stavudine In Subj Prev Trtd W/ 141w94/Vx-478National Center For Research Resources1999–2002
Phase II Prolong Virologic Success &Optn For Failure In HIV Sub On IndinavirNational Center For Research Resources1999–2002
Actg384 Protease Inhibitor &/Or NON Nucleoside Reverse Trans InhibitorNational Center For Research Resources1999–2002
ACTG 398, Phase II Trial Of Amprenavir As PART Of Dual Protease InhibNational Center For Research Resources1999–2002
ACTG 362 Trials Of Azithromycin Prophylaxis To Prevent MAC DiseaseNational Center For Research Resources1999–2002
ACTG 323 Fluconazole As Therapy For Oropharyngeal CandidiasisNational Center For Research Resources1999–2002
A5025 Phase II Random Study Of Hydroxyurea In Subj On Potent AntiretroviralsNational Center For Research Resources1999–2002
Actg368 Indinavir Sulfate, Dmp266 &1592u89 In HIV Infected SubjectsNational Center For Research Resources1998–2002
3 Maintenence Regimens For HIV Subjects REC Zidovudine, Lamivudine, IndinavirNational Center For Research Resources1998–2002
Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases1997–2002
Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1999–2001
Actg347 Phase II Study Of 141w94/Vx478 Monotherapy VS 141w94/Vx + ZidovudineNational Center For Research Resources1998–2000
Virologic Responses To New Nucleoside Regimens After ZDV Or DDI MonotherapyNational Center For Research Resources1997–2000
Influence Of Risk Status For Disease Progression On The Response To InterventionNational Center For Research Resources1997–2000
ACTG 320 Phase III Indinavir SulfateNational Center For Research Resources1997–2000
ACTG 315 Ritonavir, Zidovudine And Lamivudine In Advanced HIV 1 DiseaseNational Center For Research Resources1997–2000
ACTG 285 Stem Cell Mobilization And Harvesting With FilgrastimNational Center For Research Resources1997–2000
Safety, Tolerability And Pharmacokinetics Of Thalidomide In HIV1 PatientsNational Center For Research Resources1998–1999
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
Zdv/Ddi Regimens On Measures Of Viral Burden In Early HIV-1 InfectionNational Center For Research Resources1997–1999
Phase II/III Double-Blind Study Of Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources1997–1999
Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1997–1999
D4T VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Infected PatientsNational Center For Research Resources1997–1999
ACTG 333--Hard Capsule And Soft Capsule Saquinavir VS IndinavirNational Center For Research Resources1997–1999
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–1999
Dapsone And Atovaquone Study For PCP In HIV Infected PatientsNational Center For Research Resources1996–1999
Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1996–1998
Trial To Evaluate Activity Of 141W94 In Patients With HIV InfectionNational Center For Research Resources1997
Random Dbl-Bld, Combination Of Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1997
Phase I/II Open-Label Trial Of Delavirdine Mesylate (Dlv, U-90152s)National Center For Research Resources1997
Evaluation Of STD Therapy VS STD Therapy W/Msl 109 In AIDS Patients W/CmvNational Center For Research Resources1997
Delavirdine And ZDV Or Didanosine VS ZDV And DDI Combination TherapyNational Center For Research Resources1997
1592U89 Alone And With Retrovir For HIV Infection (Glaxo/Wellcome (131-002)National Center For Research Resources1997
Phase II/III Clarithromycin Regimens For MAC In HIV Positive PatientsNational Center For Research Resources1996–1997
HIV-1 Derived Immunogens In Infected Individuals W/500 CD4 Cells/Mm3National Center For Research Resources1996–1997
ACTG 175--Monotherapy VS Combination Therapy In HIV PTS, CD4 200-500National Center For Research Resources1996–1997
Conference On Immunopathogenesis Of HIV InfectionNational Institute Of Allergy And Infectious Diseases1996
Short Term Clinical And Virologic Significance Of ZDV ResistanceNational Center For Research Resources1996
ACTG 303--Influence Of Risk Status For Disease ProgressionNational Center For Research Resources1996
ACTG 290-D4t VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Positive PatientsNational Center For Research Resources1996
ACTG 276--Various Zdv/Ddi Regimens On Measures Of Viral BurdenNational Center For Research Resources1996
ACTG 261--Delavirdine And ZDV VS ZDV And DDI Combination TherapyNational Center For Research Resources1996
ACTG 260--Phase I/II Trial Of Delavirdine MesylateNational Center For Research Resources1996
ACTG 259--Phase II SC 49483 With ZDV Versus ZDVNational Center For Research Resources1996
ACTG 248--Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1996
ACTG 241--Ddi PLUS Nevirapine Versus ZDV PLUS DDINational Center For Research Resources1996
ACTG 209--Phase I/II Trial Vaccine Therapy In HIV1 Infected IndividualsNational Center For Research Resources1996
ACTG 206--Alpha Interferon With DDI For Patients With Kaposis SarcomaNational Center For Research Resources1996
ACTG 204a--Valacyclovir Hydrocholoride Study In HIV Positive PatientsNational Center For Research Resources1996
ACTG 193a--Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1996
1592U89 Alone And With Retrovir For HIV InfectionNational Center For Research Resources1996
Ribozymes As Molecular Therapies For AIDSNational Institute Of Allergy And Infectious Diseases1994–1996
AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
Cell Mediated Immune Response To Human RetrovirusesNational Cancer Institute1990–1994
Colorado AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
AIDS &Related Research 1 Study SectionCenter For Scientific Review1990
Cellular Immune Response To HIVNational Cancer Institute1987–1989
Human T-Cell Leukemia Virus--Virus-Host InteractionsNational Cancer Institute1985–1986

Committees

Chair, Microbiology and Infectious Diseases, B 2019 - 2023
Chair, NIH Drug Discovery and Resistance (DDR) Study Section 2011 - 2013
Member, Scientific Advisory Board, PEPFAR, US Department of State 2011 - 2013